A phase I randomized, multicenter trial of CPX in adult subjects with mild cystic fibrosis (Q43861075)

27 November 2017

A phase I randomized, multicenter trial of CPX in adult subjects with mild cystic fibrosis (English)

1 reference

multicenter clinical trial

27 November 2017

phase I clinical trial

0 references

cystic fibrosis

0 references

1 reference

Nael A McCarty

1

1 reference

27 November 2017

Thomas A Standaert

2

1 reference

27 November 2017

Mary Teresi

3

1 reference

27 November 2017

Cynthia Tuthill

4

1 reference

27 November 2017

Janice Launspach

5

1 reference

27 November 2017

Thomas J Kelley

6

1 reference

27 November 2017

Laura J H Milgram

7

1 reference

27 November 2017

Kathleen A Hilliard

8

1 reference

27 November 2017

Warren E Regelmann

9

1 reference

27 November 2017

Mark R Weatherly

10

1 reference

27 November 2017

Moira L Aitken

11

1 reference

27 November 2017

Michael W Konstan

12

1 reference

27 November 2017

Richard C Ahrens

13

1 reference

27 November 2017

1 February 2002

1 reference

27 November 2017

Pediatric Pulmonology

1 reference

27 November 2017

33

1 reference

27 November 2017

90-98

1 reference

27 November 2017

2

1 reference

Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA

27 November 2017

1 reference

https://api.crossref.org/works/10.1002%2FPPUL.10041

Molecular mechanisms of CFTR chloride channel dysfunction in cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPPUL.10041

Defective intracellular transport and processing of CFTR is the molecular basis of most cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPPUL.10041

Chloride Conductance Expressed by ΔF508 and Other Mutant CFTRs In Xenopus Oocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPPUL.10041

Deletion of phenylalanine 508 causes attenuated phosphorylation-dependent activation of CFTR chloride channels

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPPUL.10041

Future pharmacological treatment of cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPPUL.10041

Cystic fibrosis: molecular biology and therapeutic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPPUL.10041

A1 adenosine-receptor antagonists activate chloride efflux from cystic fibrosis cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPPUL.10041

A1 receptor antagonist 8-cyclopentyl-1,3-dipropylxanthine selectively activates chloride efflux from human epithelial and mouse fibroblast cell lines expressing the cystic fibrosis transmembrane regulator delta F508 mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPPUL.10041

Activation of deltaF508 CFTR in a cystic fibrosis respiratory epithelial cell line by 4-phenylbutyrate, genistein and CPX.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPPUL.10041

Direct activation of cystic fibrosis transmembrane conductance regulator channels by 8-cyclopentyl-1,3-dipropylxanthine (CPX) and 1,3-diallyl-8-cyclohexylxanthine (DAX).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPPUL.10041

Activation of wild-type and deltaF508-CFTR by phosphodiesterase inhibitors through cAMP-dependent and -independent mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPPUL.10041

No evidence for direct activation of the cystic fibrosis transmembrane conductance regulator by 8-cyclopentyl-1,3-dipropylxanthine

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPPUL.10041

Stimulation by alkylxanthines of chloride efflux in CFPAC-1 cells does not involve A1 adenosine receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPPUL.10041

Cystic fibrosis and the use of pharmacogenomics to determine surrogate endpoints for drug discovery

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPPUL.10041

Use of nasal potential difference and sweat chloride as outcome measures in multicenter clinical trials in subjects with cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPPUL.10041

In vivo nasal potential difference: techniques and protocols for assessing efficacy of gene transfer in cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPPUL.10041

Altered chloride ion channel kinetics associated with the ΔF508 cystic fibrosis mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPPUL.10041

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPPUL.10041

8-cyclopentyl-1,3-dipropylxanthine and other xanthines differentially bind to the wild-type and delta F508 first nucleotide binding fold (NBF-1) domains of the cystic fibrosis transmembrane conductance regulator

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPPUL.10041

21 January 2018

Identifiers

DOI

10.1002/PPUL.10041

1 reference

27 November 2017

1 reference